{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:24:54Z","timestamp":1793953494868,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012326","name":"International Science and Technology Cooperation Programme","doi-asserted-by":"publisher","award":["252102521060"],"award-info":[{"award-number":["252102521060"]}],"id":[{"id":"10.13039\/501100012326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010950","name":"Department of Science and Technology of Henan Province","doi-asserted-by":"publisher","award":["241111313500"],"award-info":[{"award-number":["241111313500"]}],"id":[{"id":"10.13039\/501100010950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pnpbp.2026.111683","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:52:11Z","timestamp":1774630331000},"page":"111683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Serum IGF-1 and anxiety trajectories in Parkinson's disease"],"prefix":"10.1016","volume":"146","author":[{"given":"Shuai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Feng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pnpbp.2026.111683_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12760","article-title":"Impaired brain insulin signalling in Parkinson\u2019s disease","volume":"48","author":"Bassil","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111683_bb0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12967-020-02223-0","article-title":"Is insulin-like growth factor-1 involved in Parkinson\u2019s disease development?","volume":"18","author":"Castilla-Cort\u00e1zar","year":"2020","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111683_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/nu10060714","article-title":"Supplementation of blackcurrant anthocyanins increased cyclic Glycine-proline in the cerebrospinal fluid of Parkinson patients: potential treatment to improve insulin-like growth Factor-1 function","volume":"10","author":"Fan","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111683_bb0020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10072-022-06427-8","article-title":"Predictors of anxiety in Parkinson\u2019s disease: results from a 3-year longitudinal cohort study","volume":"44","author":"Gibson","year":"2023","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111683_bb0025","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/jnnp.2009.175752","article-title":"Increased serum insulin-like growth factor 1 in early idiopathic Parkinson\u2019s disease","volume":"81","author":"Godau","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111683_bb0030","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10072-024-07835-8","article-title":"Association between serum IGF-1 levels and non-motor symptoms in Parkinson\u2019s disease","volume":"46","author":"Gu","year":"2025","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111683_bb0035","article-title":"Cyclic glycine-proline (cGP) normalises insulin-like growth Factor-1 (IGF-1) function: clinical significance in the ageing brain and in age-related neurological conditions","volume":"28","author":"Guan","year":"2023","journal-title":"Molecules (Basel, Switz.)"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111683_bb0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12888-020-02636-7","article-title":"Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study","volume":"20","author":"Levada","year":"2020","journal-title":"BMC Psychiatry."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111683_bb0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12877-024-04854-0","article-title":"Parkinson\u2019s disease with anxiety: clinical characteristics and their correlation with oxidative stress, inflammation, and pathological proteins","volume":"24","author":"Lian","year":"2024","journal-title":"BMC Geriatr."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111683_bb0050","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/sj.npp.1301358","article-title":"Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects","volume":"32","author":"Malberg","year":"2007","journal-title":"Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111683_bb0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jocn.2009.08.013","article-title":"Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson\u2019s disease","volume":"17","author":"Mashayekhi","year":"2010","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111683_bb0060","article-title":"Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression","volume":"185(50-60","author":"Mitschelen","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2026.111683_bb0065","article-title":"The neuropathological basis of anxiety in Parkinson\u2019s disease","volume":"144(110048","author":"Overton","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111683_bb0070","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00415-013-6851-0","article-title":"Insulin-like growth factor-1 and progression of motor symptoms in early, drug-na\u00efve Parkinson\u2019s disease","volume":"260","author":"Picillo","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.pnpbp.2026.111683_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.parkreldis.2017.06.024","article-title":"Predictors of anxiety in early-stage Parkinson\u2019s disease - results from the first two years of a prospective cohort study","volume":"43","author":"Rutten","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111683_bb0080","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/14656566.2018.1485650","article-title":"Pharmacological interventions for anxiety in Parkinson\u2019s disease sufferers","volume":"19","author":"Sawada","year":"2018","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pnpbp.2026.111683_bb0085","article-title":"Insulin-like growth factor in Parkinson\u2019s disease is related to nonmotor symptoms and the volume of specific brain areas","volume":"783(136735","author":"Shi","year":"2022","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111683_bb0090","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10072-022-06490-1","article-title":"Correlation between serum IGF-1 and EGF levels and neuropsychiatric and cognitive in Parkinson\u2019s disease patients","volume":"44","author":"Shi","year":"2023","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111683_bb0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/ane.13091","article-title":"Serum insulin-like growth factor-1 levels in neurodegenerative diseases","volume":"139","author":"Suzuki","year":"2019","journal-title":"Acta Neurol. Scand."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111683_bb0100","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/brain\/awae313","article-title":"Basal ganglia theta power indexes trait anxiety in people with Parkinson\u2019s disease","volume":"148","author":"Swinnen","year":"2025","journal-title":"Brain J. Neurol."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111683_bb0105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111683_bb0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-0041-1722840","article-title":"Anxiety in Parkinson\u2019s disease: correlation with depression and quality of life","volume":"12","author":"Upneja","year":"2021","journal-title":"J. Neurosci. Rural Pract."},{"key":"10.1016\/j.pnpbp.2026.111683_bb0115","article-title":"Neural correlates of anxiety symptoms in mild Parkinson\u2019s disease: a prospective longitudinal voxel-based morphometry study","volume":"371(131-136","author":"Wee","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111683_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.2949","article-title":"Association of IGF1 gene polymorphism with Parkinson\u2019s disease in a Han Chinese population","volume":"19","author":"Xiao","year":"2017","journal-title":"J. Gene Med."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111683_bb0125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ene.13217","article-title":"Onset and evolution of anxiety in Parkinson\u2019s disease","volume":"24","author":"Zhu","year":"2017","journal-title":"Eur. J. Neurol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:34:28Z","timestamp":1793950468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"alternative-id":["S0278584626000795"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111683","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum IGF-1 and anxiety trajectories in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111683"}}